Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Accumulated Expenses (2022 - 2026)

Sagimet Biosciences' Accumulated Expenses history spans 5 years, with the latest figure at $3.0 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 344.36% to $3.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Mar 2026, up 344.36% year-over-year, with the annual reading at $3.7 million for FY2025, 173.49% up from the prior year.
  • Accumulated Expenses came in at $3.0 million for Q1 2026, down from $3.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.4 million in Q4 2023 to a low of $109000.0 in Q3 2025.
  • The 5-year median for Accumulated Expenses is $3.0 million (2026), against an average of $2.7 million.
  • Year-over-year, Accumulated Expenses crashed 86.61% in 2025 and then skyrocketed 344.36% in 2026.
  • Sagimet Biosciences' Accumulated Expenses stood at $4.0 million in 2022, then soared by 34.37% to $5.4 million in 2023, then tumbled by 74.87% to $1.4 million in 2024, then surged by 173.49% to $3.7 million in 2025, then fell by 20.44% to $3.0 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Accumulated Expenses are $3.0 million (Q1 2026), $3.7 million (Q4 2025), and $109000.0 (Q3 2025).